Biogen Inc (BIIB) Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release

Newsdesk: